AU2019229583B2 - Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases - Google Patents

Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases Download PDF

Info

Publication number
AU2019229583B2
AU2019229583B2 AU2019229583A AU2019229583A AU2019229583B2 AU 2019229583 B2 AU2019229583 B2 AU 2019229583B2 AU 2019229583 A AU2019229583 A AU 2019229583A AU 2019229583 A AU2019229583 A AU 2019229583A AU 2019229583 B2 AU2019229583 B2 AU 2019229583B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
stereoisomer
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019229583A
Other languages
English (en)
Other versions
AU2019229583A1 (en
Inventor
William R. Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Europe GmbH
Original Assignee
Amgen Europe GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Europe GmbH filed Critical Amgen Europe GmbH
Publication of AU2019229583A1 publication Critical patent/AU2019229583A1/en
Application granted granted Critical
Publication of AU2019229583B2 publication Critical patent/AU2019229583B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
    • C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
    • C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AU2019229583A 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases Active AU2019229583B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639650P 2018-03-07 2018-03-07
US62/639,650 2018-03-07
PCT/EP2019/055576 WO2019170750A1 (en) 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2019229583A1 AU2019229583A1 (en) 2020-09-10
AU2019229583B2 true AU2019229583B2 (en) 2024-06-13

Family

ID=65894963

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019229583A Active AU2019229583B2 (en) 2018-03-07 2019-03-06 Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases

Country Status (11)

Country Link
US (1) US11639332B2 (cg-RX-API-DMAC10.html)
EP (1) EP3762365B1 (cg-RX-API-DMAC10.html)
JP (1) JP7396991B2 (cg-RX-API-DMAC10.html)
AR (1) AR114666A1 (cg-RX-API-DMAC10.html)
AU (1) AU2019229583B2 (cg-RX-API-DMAC10.html)
CA (1) CA3093196A1 (cg-RX-API-DMAC10.html)
ES (1) ES2987705T3 (cg-RX-API-DMAC10.html)
MA (1) MA52266A (cg-RX-API-DMAC10.html)
MX (1) MX2020009288A (cg-RX-API-DMAC10.html)
TW (1) TW202000646A (cg-RX-API-DMAC10.html)
WO (1) WO2019170750A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118370746A (zh) * 2024-04-25 2024-07-23 江苏省中医院 马尿酸在制备溃疡性结肠炎治疗药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472965A (en) 1949-06-14 Metallized tetrakisazo dyes
US3951943A (en) 1974-03-18 1976-04-20 Chemetron Corporation Coupling process in the preparation of disazo diimides
EP0856562A1 (en) 1997-01-31 1998-08-05 Hodogaya Chemical Co Ltd Recording liquid and novel metal complex compound contained therein
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
KR20030026936A (ko) * 2000-06-29 2003-04-03 니폰 가야꾸 가부시끼가이샤 색소증감 광전 변환소자
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
AU2008270363A1 (en) * 2007-06-29 2009-01-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Targeting diazo prodrugs for the treatment of gastrointestinal diseases
DK2276483T3 (da) 2008-03-27 2014-06-10 Celgene Corp Faste former, omfattende (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindolin-1,3-dion, sammensætninger deraf og anvendelser deraf
WO2012083153A1 (en) * 2010-12-16 2012-06-21 Nektar Therapeutics Oligomer-containing apremilast moiety compounds
ES2673114T3 (es) 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas

Also Published As

Publication number Publication date
ES2987705T3 (es) 2024-11-15
JP7396991B2 (ja) 2023-12-12
JP2021517134A (ja) 2021-07-15
AR114666A1 (es) 2020-09-30
EP3762365B1 (en) 2024-02-21
US11639332B2 (en) 2023-05-02
AU2019229583A1 (en) 2020-09-10
MA52266A (fr) 2021-01-13
TW202000646A (zh) 2020-01-01
US20200392082A1 (en) 2020-12-17
CA3093196A1 (en) 2019-09-12
MX2020009288A (es) 2020-09-28
EP3762365A1 (en) 2021-01-13
WO2019170750A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
JP6391071B2 (ja) シスタチオニン−γ−リアーゼ(CSE)阻害剤
ES2254470T3 (es) Compuestos inmunorreguladores, derivados de los mismos y su uso.
US20130224151A1 (en) Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
US20090325973A1 (en) Formulations containing pyridazine compounds
US20100168120A1 (en) Salts of pyridazine compounds
ES2735992T3 (es) Compuestos de unión a NHE3 y procedimientos para inhibir el transporte de fosfatos
FI61479C (fi) Foerfarande foer framstaellning av spasmolytiska nya d,l-tyrosinderivat
BR112019020691A2 (pt) Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma
BR112020010429A2 (pt) uso de agonista de kor em combinação com agonista de mor na preparação de fármaco para tratamento da dor
CN103608014A (zh) 激酶抑制剂在治疗和预防炎症疾病中的用途
AU2020344820A1 (en) Use of NMN for the prevention and/or treatment of pain, and corresponding compositions
BR112020014584A2 (pt) inibição do canal iônico do receptor de potencial transitório a1
ES2307626T3 (es) Agente terapeutico o preventivo para enfermedades del sistema disgestivo que contiene un derivado de diaminotrifluorometilpiridina.
BR112019000290B1 (pt) Prófármacos de fósforo dos estimuladores da sgc
JP2009523149A (ja) mTOR阻害剤および抗葉酸化合物の組み合わせ
US11639332B2 (en) Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases
WO2023142729A1 (zh) 呋喃核糖基吡啶衍生物用于预防或治疗癫痫或惊厥的用途
TWI296522B (en) Colonic motor dysfunction remedies comprising aminothiazole derivatives as active ingredients
BR112021001984A2 (pt) composto, combinação, composição farmacêutica, conjunto de partes, uso de composto, e, método para tratamento de uma doença resultante de inflamação patológica
EP3837008B1 (en) Substituted benzamides and their use in therapy
ES2978226T3 (es) Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
CN119925347A (zh) 化合物Pladienolide B作为抗蓖麻毒素保护剂的医药用途
WO2024002112A1 (zh) 一种治疗猫冠状或杯状病毒感染的方法
CN113861194B (zh) 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用
WO2024175053A1 (zh) 治疗或预防败血症或与败血症相关的病情的化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)